Cargando…
Risk analysis of fluctuating hypercalcemia after leukapheresis in cellular therapy
Optimized management of citrate-induced hypocalcemia is required to provide safe leukapheresis. We prospectively analyzed subjects who underwent leukapheresis for cytotherapy, and evaluated serum ionized (iCa) concentrations before, at the end of, and 1 h after leukapheresis. During leukapheresis, c...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10495341/ https://www.ncbi.nlm.nih.gov/pubmed/37696885 http://dx.doi.org/10.1038/s41598-023-42159-1 |
_version_ | 1785104872531558400 |
---|---|
author | Jo, Tomoyasu Arai, Yasuyuki Kitawaki, Toshio Nishikori, Momoko Mizumoto, Chisaki Kanda, Junya Yamashita, Kouhei Nagao, Miki Takaori-Kondo, Akifumi |
author_facet | Jo, Tomoyasu Arai, Yasuyuki Kitawaki, Toshio Nishikori, Momoko Mizumoto, Chisaki Kanda, Junya Yamashita, Kouhei Nagao, Miki Takaori-Kondo, Akifumi |
author_sort | Jo, Tomoyasu |
collection | PubMed |
description | Optimized management of citrate-induced hypocalcemia is required to provide safe leukapheresis. We prospectively analyzed subjects who underwent leukapheresis for cytotherapy, and evaluated serum ionized (iCa) concentrations before, at the end of, and 1 h after leukapheresis. During leukapheresis, calcium gluconate solution was continuously supplemented intravenously with hourly measurement of iCa. 76 patients including 49 lymphapheresis for chimeric antigen receptor T-cell therapy and 27 stem cell collections were enrolled. Median processing blood volume was 10 L (range, 6–15 L). Fluctuating hypercalcemia, in which the iCa concentration rose above its upper limit 1 h after leukapheresis, was observed in 58 subjects (76.3%). Multivariate analysis revealed that higher ratios of processing blood volume to body weight, more rapid calcium supplementation, and lower iCa concentration at the end of leukapheresis significantly increased elevation of serum iCa concentration by 1 h after leukapheresis. Based on multivariate analyses, we developed a formula and a diagram that accurately estimates serum iCa concentration 1 h post-leukapheresis. This suggests optimal targets for iCa concentration and calcium supplementation rates. In cases with high ratios of processing blood volume to body weight, slowing the rate of blood processing, rather than increasing calcium supplementation should safely alleviate hypocalcemia during leukapheresis without inducing hypercalcemia thereafter. |
format | Online Article Text |
id | pubmed-10495341 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-104953412023-09-13 Risk analysis of fluctuating hypercalcemia after leukapheresis in cellular therapy Jo, Tomoyasu Arai, Yasuyuki Kitawaki, Toshio Nishikori, Momoko Mizumoto, Chisaki Kanda, Junya Yamashita, Kouhei Nagao, Miki Takaori-Kondo, Akifumi Sci Rep Article Optimized management of citrate-induced hypocalcemia is required to provide safe leukapheresis. We prospectively analyzed subjects who underwent leukapheresis for cytotherapy, and evaluated serum ionized (iCa) concentrations before, at the end of, and 1 h after leukapheresis. During leukapheresis, calcium gluconate solution was continuously supplemented intravenously with hourly measurement of iCa. 76 patients including 49 lymphapheresis for chimeric antigen receptor T-cell therapy and 27 stem cell collections were enrolled. Median processing blood volume was 10 L (range, 6–15 L). Fluctuating hypercalcemia, in which the iCa concentration rose above its upper limit 1 h after leukapheresis, was observed in 58 subjects (76.3%). Multivariate analysis revealed that higher ratios of processing blood volume to body weight, more rapid calcium supplementation, and lower iCa concentration at the end of leukapheresis significantly increased elevation of serum iCa concentration by 1 h after leukapheresis. Based on multivariate analyses, we developed a formula and a diagram that accurately estimates serum iCa concentration 1 h post-leukapheresis. This suggests optimal targets for iCa concentration and calcium supplementation rates. In cases with high ratios of processing blood volume to body weight, slowing the rate of blood processing, rather than increasing calcium supplementation should safely alleviate hypocalcemia during leukapheresis without inducing hypercalcemia thereafter. Nature Publishing Group UK 2023-09-11 /pmc/articles/PMC10495341/ /pubmed/37696885 http://dx.doi.org/10.1038/s41598-023-42159-1 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Jo, Tomoyasu Arai, Yasuyuki Kitawaki, Toshio Nishikori, Momoko Mizumoto, Chisaki Kanda, Junya Yamashita, Kouhei Nagao, Miki Takaori-Kondo, Akifumi Risk analysis of fluctuating hypercalcemia after leukapheresis in cellular therapy |
title | Risk analysis of fluctuating hypercalcemia after leukapheresis in cellular therapy |
title_full | Risk analysis of fluctuating hypercalcemia after leukapheresis in cellular therapy |
title_fullStr | Risk analysis of fluctuating hypercalcemia after leukapheresis in cellular therapy |
title_full_unstemmed | Risk analysis of fluctuating hypercalcemia after leukapheresis in cellular therapy |
title_short | Risk analysis of fluctuating hypercalcemia after leukapheresis in cellular therapy |
title_sort | risk analysis of fluctuating hypercalcemia after leukapheresis in cellular therapy |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10495341/ https://www.ncbi.nlm.nih.gov/pubmed/37696885 http://dx.doi.org/10.1038/s41598-023-42159-1 |
work_keys_str_mv | AT jotomoyasu riskanalysisoffluctuatinghypercalcemiaafterleukapheresisincellulartherapy AT araiyasuyuki riskanalysisoffluctuatinghypercalcemiaafterleukapheresisincellulartherapy AT kitawakitoshio riskanalysisoffluctuatinghypercalcemiaafterleukapheresisincellulartherapy AT nishikorimomoko riskanalysisoffluctuatinghypercalcemiaafterleukapheresisincellulartherapy AT mizumotochisaki riskanalysisoffluctuatinghypercalcemiaafterleukapheresisincellulartherapy AT kandajunya riskanalysisoffluctuatinghypercalcemiaafterleukapheresisincellulartherapy AT yamashitakouhei riskanalysisoffluctuatinghypercalcemiaafterleukapheresisincellulartherapy AT nagaomiki riskanalysisoffluctuatinghypercalcemiaafterleukapheresisincellulartherapy AT takaorikondoakifumi riskanalysisoffluctuatinghypercalcemiaafterleukapheresisincellulartherapy |